tradingkey.logo
tradingkey.logo
Search

Jazz Pharmaceuticals PLC

JAZZ
Add to Watchlist
230.490USD
+0.640+0.28%
Market hours ETQuotes delayed by 15 min
14.16BMarket Cap
558.98P/E TTM

TradingKey Stock Score of Jazz Pharmaceuticals PLC

Currency: USD Updated: 2026-06-24

Key Insights

Jazz Pharmaceuticals PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 23 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 258.27.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Jazz Pharmaceuticals PLC's Score

Industry at a Glance

Industry Ranking
23 / 157
Overall Ranking
62 / 4571
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Jazz Pharmaceuticals PLC Highlights

StrengthsRisks
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 557.43, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.31M shares, decreasing 1.06% quarter-over-quarter.
Held by Tweedy Browne
Star Investor Tweedy Browne holds 47.90K shares of this stock.

Analyst Rating

Based on 19 analysts
Buy
Current Rating
258.275
Target Price
+14.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Jazz Pharmaceuticals PLC?

The TradingKey Stock Score provides a comprehensive assessment of Jazz Pharmaceuticals PLC based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Jazz Pharmaceuticals PLC’s performance and outlook.

How do we generate the financial health score of Jazz Pharmaceuticals PLC?

To generate the financial health score of Jazz Pharmaceuticals PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Jazz Pharmaceuticals PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Jazz Pharmaceuticals PLC.

How do we generate the company valuation score of Jazz Pharmaceuticals PLC?

To generate the company valuation score of Jazz Pharmaceuticals PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Jazz Pharmaceuticals PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Jazz Pharmaceuticals PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Jazz Pharmaceuticals PLC.

How do we generate the earnings forecast score of Jazz Pharmaceuticals PLC?

To calculate the earnings forecast score of Jazz Pharmaceuticals PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Jazz Pharmaceuticals PLC’s future.

How do we generate the price momentum score of Jazz Pharmaceuticals PLC?

When generating the price momentum score for Jazz Pharmaceuticals PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Jazz Pharmaceuticals PLC’s prices. A higher score indicates a more stable short-term price trend for Jazz Pharmaceuticals PLC.

How do we generate the institutional confidence score of Jazz Pharmaceuticals PLC?

To generate the institutional confidence score of Jazz Pharmaceuticals PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Jazz Pharmaceuticals PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Jazz Pharmaceuticals PLC.

How do we generate the risk management score of Jazz Pharmaceuticals PLC?

To assess the risk management score of Jazz Pharmaceuticals PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Jazz Pharmaceuticals PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Jazz Pharmaceuticals PLC.
KeyAI